This phase III study is being conducted to confirm the efficacy and safety of AM-101 in the treatment of peripheral tinnitus in the acute stage (up to 3 months from onset).
TACTT2 (US, CA, CZ, KR, TR, IL):
Tinnitus onset no longer than 3 months prior to randomization
Estimated Enrollment: 330
Study Start Date: February 2014
Estimated Study Completion Date: March 2016
Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)